Kenneth Tew to Prodrugs
This is a "connection" page, showing publications Kenneth Tew has written about Prodrugs.
Connection Strength
1.499
-
A glutathione S-transferase pi-activated prodrug causes kinase activation concurrent with S-glutathionylation of proteins. Mol Pharmacol. 2006 Feb; 69(2):501-8.
Score: 0.251
-
TLK-286: a novel glutathione S-transferase-activated prodrug. Expert Opin Investig Drugs. 2005 Aug; 14(8):1047-54.
Score: 0.246
-
Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug. Mol Pharmacol. 2004 May; 65(5):1070-9.
Score: 0.226
-
Efficacy of a glutathione S-transferase pi-activated prodrug in platinum-resistant ovarian cancer cells. Mol Cancer Ther. 2002 Oct; 1(12):1089-95.
Score: 0.202
-
Cellular response to a glutathione S-transferase P1-1 activated prodrug. Mol Pharmacol. 2000 Jul; 58(1):167-74.
Score: 0.173
-
Chemical Reactivity Window Determines Prodrug Efficiency toward Glutathione Transferase Overexpressing Cancer Cells. Mol Pharm. 2016 06 06; 13(6):2010-25.
Score: 0.129
-
Regulatory functions of glutathione S-transferase P1-1 unrelated to detoxification. Drug Metab Rev. 2011 May; 43(2):179-93.
Score: 0.090
-
Cellular resistance to a nitric oxide releasing glutathione S-transferase P-activated prodrug, PABA/NO. Invest New Drugs. 2011 Oct; 29(5):719-29.
Score: 0.085
-
Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets. Methods Enzymol. 2005; 401:287-307.
Score: 0.059
-
Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. Cancer Res. 1998 Jun 15; 58(12):2568-75.
Score: 0.038